We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.66B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
+$327M
(+24%)
Cap. Flow
+$308M
Cap. Flow
% of AUM
18.5%
Top 10 Holdings %
Top 10 Hldgs %
40.47%
Holding
329
New
71
Increased
98
Reduced
59
Closed
29
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 90.27% |
| 2 | Financials | 1.54% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Tango Therapeutics
TNGX
$4.73B
| $1.05M | 0.06% |
50,000
-90,021
| -64% | -$1.25M |
|
152
Tenaya Therapeutics
TNYA
$179M
| $1.04M | 0.06% |
1,507,800
+2,500
| +0.2% | +$1.84K |
|
|
BSAAU
153
BEST SPAC I Acquisition Corp Unit
BSAAU
$67.6M
| $1.04M | 0.06% |
100,000
| – | – |
|
154
McKesson
MCK
$96.5B
| $1.04M | 0.06% |
1,200
| – | – |
|
155
BioMarin Pharmaceuticals
BMRN
$11.6B
| $1.03M | 0.06% |
18,200
+5,300
| +41% | +$309K |
|
|
ORKA
156
Oruka Therapeutics
ORKA
$5.05B
| $1.02M | 0.06% |
20,840
| – | – |
|
157
Electronic Arts
EA
$52B
| $1.01M | 0.06% |
4,936
| – | – |
|
|
158
Fulcrum Therapeutics
FULC
$241M
| $1M | 0.06% |
130,560
-1,123,189
| -90% | -$10.4M |
|
159
BioCryst Pharmaceuticals
BCRX
$2.34B
| $1,000K | 0.06% |
105,000
+60,000
| +133% | +$466K |
|
160
Guardant Health
GH
$21.4B
| $924K | 0.06% |
10,000
+3,000
| +43% | +$301K |
|
|
CBIO
161
Crescent Biopharma
CBIO
$452M
| $924K | 0.06% |
50,273
-555,727
| -92% | -$6.38M |
|
162
Context Therapeutics
CNTX
$56.3M
| $920K | 0.06% |
351,094
| – | – |
|
163
enGene Therapeutics
ENGN
$129M
| $910K | 0.05% |
133,686
-170,000
| -56% | -$1.51M |
|
|
SLN
164
Silence Therapeutics
SLN
$491M
| $907K | 0.05% |
172,157
+148,514
| +628% | +$818K |
|
165
Alexandria Real Estate Equities
ARE
$8.62B
| $905K | 0.05% |
19,500
+3,200
| +20% | +$169K |
|
166
CALL
Keen Vision Acquisition Corp
KVAC
$68M
| $900K | 0.05% |
75,000
| – | – |
|
167
iBio
IBIO
$66.1M
| $893K | 0.05% |
469,878
+64,347
| +16% | +$149K |
|
168
BioNTech
BNTX
$23.3B
| $889K | 0.05% |
10,000
| – | – |
|
169
Gilead Sciences
GILD
$166B
| $885K | 0.05% |
6,351
-315
| -5% | -$44.1K |
|
170
Nurix Therapeutics
NRIX
$2.45B
| $869K | 0.05% |
56,070
-16,000
| -22% | -$265K |
|
171
Dyne Therapeutics
DYN
$3.8B
| $861K | 0.05% |
47,463
+4,789
| +11% | +$82.6K |
|
172
Intuitive Surgical
ISRG
$143B
| $844K | 0.05% |
1,830
+810
| +79% | +$410K |
|
|
ANL
173
Adlai Nortye
ANL
$717M
| $816K | 0.05% |
+117,909
| New | +$788K |
|
|
WW
174
WW International
WW
$153M
| $793K | 0.05% |
57,700
+600
| +1% | +$13.4K |
|
|
RNA
175
Atrium Therapeutics
RNA
$206M
| $771K | 0.05% |
+57,688
| New | +$811K |
|
Similar funds
GWM
GACM
RIA
CPO
NRI
JPM
GC
FA